Navigation Links
New Data Demonstrated Efficacy and Safety of Initial Combination Therapy with Welchol(R) (colesevelam HCl) and Metformin in Drug-Naive Adult Type 2 Diabetes Patients
Date:6/26/2010

PARSIPPANY, N.J., June 26 /PRNewswire/ -- Results of a new study demonstrated that initial combination therapy with Welchol® (colesevelam HCl) 3.75 g/d and metformin (initiated at 850 mg/d; uptitrated to 1700 mg/d thereafter) significantly improved glycemic and lipid control in drug-naive adult type 2 diabetes patients with high LDL cholesterol (LDL-C).  In the study, treatment with Welchol plus metformin significantly reduced mean A1C levels by 1.1 percent and LDL-C levels by 21 percent.  In addition, approximately two-thirds of patients who received Welchol plus metformin achieved the American Diabetes Association (ADA)'s glycemic goal of A1C levels less than 7 percent, which was statistically significant compared with metformin plus placebo alone.(1)  Results of the randomized, double-blind, placebo-controlled study were presented today at the 70th Scientific Sessions of the ADA in Orlando.

"In this study, early intervention with Welchol and metformin significantly reduced A1C and LDL cholesterol levels, two important risk factors for cardiovascular disease, in drug-naive adult type 2 diabetes patients with high cholesterol," said Yehuda Handelsman, MD, FACP, FACE, Medical Director of the Metabolic Institute of America in Tarzana, Calif. and investigator of the study.  "Notably, these data indicate that initial combination therapy with Welchol and metformin may represent a safe and effective option to help patients with type 2 diabetes reach glycemic and lipid goals."

About 23.6 million, or 8 percent of people in the United States, have diabetes, and approximately 90 to 95 percent of people diagnosed with diabetes have type 2 diabetes.(2)  The ADA and the Ameri
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners ADHD Rating Scale
2. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
3. Solos Endoscopy, Inc.s MammoView(TM) Product Line to be Demonstrated at the 95th Annual American College of Surgeons Clinical Congress
4. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
5. 5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
6. Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
7. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
8. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
9. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
10. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
11. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
(Date:7/10/2014)... Integrated Silicon Solution, Inc. (Nasdaq: ... IC solutions, today announced that it will host its ... 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) to ... third quarter ended June 30, 2014. To ... 6:50 a.m. Pacific time on July 24, 2014.  The ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Health, Inc. (Nasdaq: GHDX ) today announced plans ... improving the quality of diagnosis, communication and support for millions ... genetic conditions.   The subsidiary is expected to be established by ... 2013.  The new venture will be led by Randy Scott, ...
... 2012 TeDan Surgical Innovations , industry leader ... Phantom Series MIS Anterior Hip Retractor System . ... adjustable surgical arms with attachable retractors, enabling surgeons to ... a surgical assistant. Dr. Lawrence Menendez ...
Cached Medicine Technology:Genomic Health Announces Formation of New Genetics Subsidiary 2Genomic Health Announces Formation of New Genetics Subsidiary 3Genomic Health Announces Formation of New Genetics Subsidiary 4New Minimally Invasive Hip Retractor Revolutionizes Anterior Hip Replacement Procedures 2
(Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
(Date:7/12/2014)... 12, 2014 Using and carrying around ... two inventors from Ashland, Va., decided that there needed ... inspired us to conceive of our design," he said. ... KIDNEY KOVER, which provides an inconspicuous way to use ... as well as promotes comfort and peace of mind. ...
(Date:7/12/2014)... July 12, 2014 For those who are ... can readily absorb the nutrients in food. The enzymes literally ... are small enough to be absorbed by human bodies. According ... lack of enzymes in regular food is the cause of ... that was started by Michelle DelPresto, a mother of 3 ...
(Date:7/12/2014)... Doylestown Hospital recently conducted an interview ... health questions. Paddock tackles topics including main men's ... live longer than men, and testosterone replacement therapy, among ... featured on Doylestown Hospital’s website, Dr. Brad Paddock ... age. If you notice pain, bulging, or asymmetry in ...
(Date:7/12/2014)... 2014 Dubai is buzzing with the ... heading to the UAE. The National Basketball Association’s ... in the UAE from 28-31 October to lead the ... diabetes awareness. The event is being organized by Maven ... management company based in Dubai. The announcement was made ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
... ... customers with an advanced BlackBerry® smartphone paging solution. Onset METAMessage® enables Indiana Paging Network ... RIMM) via their current pager number and eliminate the need to carry two devices. ... (PRWEB) April ...
... the number of preventable patient injuries in California hospitals ... drop in malpractice claims against physicians, according to a ... Researchers studied both medical malpractice claims and adverse events ... that changes in the frequency of adverse events were ...
... Experimental treatment offers hope against cancer that returns after castration ... that a new hormone treatment could be a weapon for ... that,s resistant to surgical removal of the testicles. , ... new drug treatments have been completed, however. At this point, ...
... ... comprehensive and successful anti-obesity program, First Lady Michelle Obama’s “Let’s Move” campaign must ... , ... (Vocus) April 14, 2010 -- To be a truly comprehensive and successful ...
... , ... the impact of statins on the progression of multiple sclerosis found a lower incidence of ... disease as compared to a placebo. , ... (Vocus) April 14, 2010 -- A UCSF-led study examining the impact of statins ...
... unsavory-sounding name "corn smut" wields different weapons from its ... it infects. The discovery by Stanford researchers marks the ... pathogen. The finding upends conventional notions of how ... approaches to fighting disease not only in plants but ...
Cached Medicine News:Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 2Health News:Indiana Paging Network and Onset Technology Partner to Deliver Paging Messages to Blackberry Smartphones 3Health News:Better patient safety linked to fewer medical malpractice claims in California 2Health News:Hormone Therapy May Fight Resistant Prostate Cancer 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 2Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 3Health News:Childhood Obesity Interventions Must Begin Early, UCSF Experts Say 4Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 2Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 3Health News:Statins May Slow Progression of Multiple Sclerosis, New Study Finds 4Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 2Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 3Health News:Plant pathogen genetically tailors attacks to each part of host, say Stanford researchers 4
... The ISOPLATER® is an automatic petri ... streak and stack up to 180 ... Automated streaking results in substantial cost ... improves isolation rates, standardizes streaking procedures ...
A compact mobile System Cart gives mobility within your department. The cart accomodates the Uromac Median data processor, desktop computer, printer and provides stowage space. Patient related transd...
... by Laborie, a leading producer ... credible tracings. ICS recognized Urodynamics ... parameters. Designed especially for the ... to be quick, efficient and ...
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
Medicine Products: